Dror Limon
Overview
Explore the profile of Dror Limon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nobel H, Ofer J, Borenstein S, Limon D, Gal O, Laviv Y, et al.
J Neurooncol
. 2025 Mar;
PMID: 40072807
Purpose: To evaluate short and long-term efficacy of bevacizumab (Bev), for the treatment of radiation necrosis (RN) in patients with brain metastasis after stereotactic radiosurgery (SRS). Methods: The database of...
2.
Averbuch I, Bareket-Samish A, Goldstein D, Eizenstein S, Markel G, Rosenbaum E, et al.
Int J Radiat Oncol Biol Phys
. 2025 Feb;
PMID: 39978692
A 75-year-old man enters your clinic with a new diagnosis of high-risk localized prostate cancer. You suggest to him a state-of-the-art treatment plan: radiotherapy to the prostate and lymph nodes,...
3.
Waizman E, Dudnik E, Lavi I, Lavie I, Rotem O, Amiel A, et al.
J Neurol Sci
. 2025 Feb;
470:123398.
PMID: 39922142
Purpose: Brain metastases frequently occur in patients with non-small cell lung cancer (NSCLC) and are associated with poor prognosis and shortened overall survival, despite the advances in both imaging and...
4.
Borenstein S, Eliahou R, Amiel A, Talianski A, Ofer J, Even-Haim S, et al.
Neurooncol Adv
. 2024 Oct;
6(1):vdae128.
PMID: 39474492
Background: Meningiomas are the most common primary tumor in the central nervous system. About 15%-20% are aggressive and tend to recur and progress despite conventional treatment. Bevacizumab has been found...
5.
Limon D, Amiel A, Haim S, Gordon N, Tschernichovsky R, Stemmer S, et al.
Neurooncol Adv
. 2024 Oct;
6(1):vdae154.
PMID: 39429970
Background: Atypical and anaplastic meningiomas account for 20% of all meningioma cases. Solitary fibrous tumor (SFT) is a type of soft tissue sarcoma with similar attributes to meningioma. For patients...
6.
Laviv Y, Regev O, Kanner A, Fichman S, Limon D, Siegal T, et al.
J Neurooncol
. 2024 Sep;
171(1):201-211.
PMID: 39316315
Purpose: Angiogenesis is a crucial step in tumorigenesis of glioblastoma (GBM). Bevacizumab, an anti-vascular endothelial growth factor drug, is approved for second-line therapy for GBM. Glioma stem cells, presumably the...
7.
Lawrence Y, Miszczyk M, Dawson L, Diaz Pardo D, Aguiar A, Limon D, et al.
Lancet Oncol
. 2024 Jul;
25(8):1070-1079.
PMID: 39029483
Background: Refractory upper abdominal pain or lower back pain (retroperitoneal pain syndrome) related to celiac plexus involvement characterises pancreatic and other upper gastrointestinal malignancies and is an unmet need. We...
8.
Fredman E, Moore A, Icht O, Tschernichovsky R, Shemesh D, Bragilovski D, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jul;
120(5):1404-1409.
PMID: 39002849
Purpose: SABR-Dual is a phase-III trial with an initial phase-I safety cohort, of 2-fraction stereotactic radiotherapy (SABR) with optional magnetic resonance imaging (MRI)-based focal boost, using peri-rectal spacing, for localized...
9.
Icht O, Schlosser S, Weinstock-Sabbah M, Rephael M, Bragilovski D, Moore A, et al.
Front Oncol
. 2024 Jul;
14:1386058.
PMID: 38957327
Introduction: Precise patient positioning with image guidance (IGRT) is essential for safe prostate radiotherapy. We present the first report of utilizing a CT-visible hydrogel spacer, used to decrease rectal radiation...
10.
Fredman E, Icht O, Moore A, Bragilovski D, Kindler J, Golan S, et al.
BMC Cancer
. 2024 Apr;
24(1):431.
PMID: 38589860
Background: Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherapy (SABR)...